## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bowman-Amuah, Michel K.

Serial No: 10/647,411 Conf. No. 2655

Filed: August 25, 2003 Group Art Unit: 3688

Title:

Context sensitive advertisement

delivery framework

Docket No: 060021-376302

Examiner: Alvarez, Raquel

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56, § 1.97 and § 1.98, Applicant brings the references listed on the attached Form PTO-1449 to the examiner's attention. These references may be material to examination of the above-identified application. Please do not construe the filing of this supplemental information disclosure statement as a representation that applicant has made a search (37 C.F.R. § 1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

This Information Disclosure Statement is being submitted:

⊠	1. Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first office action on the merits, or before the mailing of a first office action after filing of a request for continued examination under 37 CFR 1.114, and therefore. Applicant believes no fee is required:
	and therefore, Applicant believes no fee is required;

2. After the period specified in paragraph (1) hereinabove of this section,	but is being
filed before the mailing date of either a final action under 37 CFR 1.113,	or a notice of

	allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and is accompanied by one of the following:					
		(a)	A stat	ement that either:		
			(i)	Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement;		
			OR			
			(ii)	No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement;		
		OR				
		(b)		ee of \$180 for filing of an Information Disclosure Statement as set forth C.F.R. 1.17(p).		
	<ol><li>After the period specified in paragraph (2) of this section, but is filed on or before payment of the issue fee and is accompanied by both:</li></ol>					
		(a)	a) A statement that either:			
			(i)	Each item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement;		
			OR			
			(ii)	No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement;		
		(b)		ee of \$180.00 for filing of an Information Disclosure Statement as set in 37 CFR 1.17(p).		
A1i	oomt v	bluou	onnrac	piete the Exeminer initialing and signing a conv of Form PTO-		

Applicant would appreciate the Examiner initialing and signing a copy of Form PTO-1449, transmitted herewith, indicating that the information has been considered and made of record herein. In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 50-1901 referencing order number 060021-376302.

Respectfully submitted,

Christopher R. Where Reg. No. 48.740

Customer No. 29838

Oppenheimer Wolff & Donnelly LLP 45 So. Seventh St., Ste. 3300

Minneapolis, Minnesota 55402

(612) 607-7237

Email: CHilberg@oppenheimer.com